We demonstrate that EVA1A deficiency promotes hepatic lipid accumulation by simultaneously enhancing fatty acid uptake and suppressing β-oxidation, ultimately driving MASLD progression in mice. Here, EVA1A is linked to metabolic dysfunction-associated steatotic liver disease.